Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 4, 2016, Pages 273-282

  Mowat, Craig ^a   Arnott, Ian ^b   Cahill, Aiden ^c   Smith, Malcolm ^d   Ahmad, Tariq ^e,f   Subramanian, Sreedhar ^g   Travis, Simon ^h   Morris, John ^c   Hamlin, John ⁱ   Dhar, Anjan ^j   Nwokolo, Chuka ^k   Edwards, Cathryn ^l   Creed, Tom ^m   Bloom, Stuart ⁿ   Yousif, Mohamed ^o   Thomas, Linzi ^p   Campbell, Simon ^q   Lewis, Stephen J ^r   Sebastian, Shaji ^s   Sen, Sandip ^t   Lal, Simon ^u   Hawkey, Chris ^v   Murray, Charles ^w   Cummings, Fraser ^x   Goh, Jason ^y   Lindsay, James O ^z   Arebi, Naila ^aa   Potts, Lindsay ^ab   McKinley, Aileen J ^d   Thomson, John M ^d   Todd, John A ^a   Collie, Mhairi ^b   Dunlop, Malcolm G ^b   Mowat, Ashley ^d   Gaya, Daniel R ^c   Winter, Jack ^c   Naismith, Graham D ^ac   Ennis, Holly ^ad   Keerie, Catriona ^ad   Lewis, Steff ^ad   Prescott, Robin J ^ad   Kennedy, Nicholas A ^b,f   Satsangi, Jack ^b   more..

^a NINEWELLS HOSPITAL   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^f UNIVERSITY OF EXETER   (United Kingdom)

^g ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ LEEDS GENERAL INFIRMARY   (United Kingdom)

^j DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^l TORBAY HOSPITAL   (United Kingdom)

^m BRISTOL ROYAL INFIRMARY   (United Kingdom)

ⁿ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^o Rotherham NHS Foundation Trust   (United Kingdom)

^p SINGLETON HOSPITAL   (United Kingdom)

^q MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^r DERRIFORD HOSPITAL   (United Kingdom)

^s HULL ROYAL INFIRMARY   (United Kingdom)

^t UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^u SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^v NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^w ROYAL FREE HOSPITAL   (United Kingdom)

^x SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^y QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^z BARTS HEALTH NHS TRUST   (United Kingdom)

^aa ST MARK S HOSPITAL   (United Kingdom)

^ab RAIGMORE HOSPITAL   (United Kingdom)

^ac ALEXANDRA HOSPITAL   (United Kingdom)

^ad UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; THIOPURINE METHYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; ILEOCECAL VALVE; INCIDENCE; INTESTINE RESECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING; TERTIARY CARE CENTER; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MERCAPTOPURINE; MIDDLE AGED; RECURRENCE; SECONDARY PREVENTION; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84996527564     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30078-4     Document Type: Article

References (26)

1. 1 Binder, V, Hendriksen, C, Kreiner, S, Prognosis in Crohn's disease—based on results from a regional patient group from the county of Copenhagen. Gut 26 (1985), 146–150.
2. 2 Vester-Andersen, MK, Prosberg, MV, Jess, T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 109 (2014), 705–714.
3. 3 Van Assche, G, Rutgeerts, P, Medical management of postoperative recurrence in Crohn's disease. Gastroenterol Clin North Am 33 (2004), 347–360.
4. 4 Post, S, Herfarth, C, Böhm, E, et al. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn's disease. Ann Surg 223 (1996), 253–260.
5. 5 Mowat, C, Cole, A, Windsor, A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 60 (2011), 571–607.
6. 6 Singh, S, Garg, SK, Pardi, DS, Wang, Z, Murad, MH, Loftus, EV, Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology 148 (2015), 64–76 e2.
7. 7 Jones, GR, Kennedy, NA, Lees, CW, Arnott, ID, Satsangi, J, Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance—progress and prospects. Aliment Pharmacol Ther 39 (2014), 1253–1265.
8. 8 Gordon, M, Taylor, K, Akobeng, AK, Thomas, AG, Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev, 8, 2014 CD010233.
9. 9 Regueiro, M, Schraut, W, Baidoo, L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136 (2009), 441–450.
10. 10 Yoshida, K, Fukunaga, K, Ikeuchi, H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 18 (2012), 1617–1623.
11. 11 De Cruz, P, Kamm, MA, Hamilton, AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 385 (2015), 1406–1417.
12. 12 Lennard-Jones, JE, Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170 (1989), 2–6.
13. 13 Dervieux, T, Boulieu, R, Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 44 (1998), 551–555.
14. 14 Rutgeerts, P, Geboes, K, Vantrappen, G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99 (1990), 956–963.
15. 15 Mary, JY, Modigliani, R, Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989), 983–989.
16. 16 D'Haens, GR, Vermeire, S, Van Assche, G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135 (2008), 1123–1129.
17. 17 Reese, GE, Nanidis, T, Borysiewicz, C, Yamamoto, T, Orchard, T, Tekkis, PP, The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 23 (2008), 1213–1221.
18. 18 Buisson, A, Chevaux, J-B, Allen, PB, Bommelaer, G, Peyrin-Biroulet, L, Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 35 (2012), 625–633.
19. 19 Hanauer, SB, Korelitz, BI, Rutgeerts, P, et al. Post-operative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine or placebo: a 2-year trial. Gastroenterology 127 (2004), 723–729.
20. 20 Ardizzone, S, Maconi, G, Sampietro, GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127 (2004), 730–740.
21. 21 Sandborn, WJ, Feagan, BG, Hanauer, SB, et al. A review of activity indices and clinical endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002), 512–530.
22. 22 Kennedy, NA, Ennis, H, Gaya, DR, Mowat, C, Arnott, IDR, Inter-observer agreement in assessment of Rutgeerts' score of endoscopic recurrence of ileal Crohn's disease: a sub-study of the TOPPIC trial. J Crohns Colitis 9 (2015), S231–S232 (abstr).
23. 23 Thomas, CW Jr, Lowry, PW, Franklin, CL, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 9 (2003), 237–245.
24. 24 Regueiro, M, Feagan, BG, Zou, B, et al., for the PREVENT Study Group. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology 150 (2016), 1568–1578.
25. 25 Ferrante, M, Papamichael, K, Duricova, D, et al. Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn's disease recurrence. J Crohns Colitis 9 (2015), 617–624.
26. 26 Parkes, GC, Whelan, K, Lindsay, JO, Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effects. J Crohns Colitis 8 (2014), 717–725.